Literature DB >> 11931418

Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis.

Y K Park1, B J Kim, S Ryu, Y H Kook, Y K Choe, G H Bai, S J Kim.   

Abstract

KRM-1648 resistant Mycobacterium tuberculosis strains were identified from a collection of rifampicin-resistant strains. Several strains had novel rpoB gene mutations in codons 512, 529 and 533 of the rpoB gene. The strains with mutations in codons 526 or 531, major mutation sites in rifampicin-resistant M. tuberculosis, were resistant to KRM-1648. Also, the strains with other mutations in the rpoB gene that were initially susceptible to KRM-1648 were prone to developing KRM-1648 resistance after further mutation. Thus, KRM-1648 is unlikely to be useful for the treatment of rifampicin-resistant tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11931418

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.

Authors:  David M Rothstein; Ronald S Farquhar; Klari Sirokman; Karen L Sondergaard; Charles Hazlett; Angelia A Doye; Judith K Gwathmey; Steve Mullin; John van Duzer; Christopher K Murphy
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.

Authors:  Robert J Suchland; Agnès Bourillon; Erick Denamur; Walter E Stamm; David M Rothstein
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Use of DNA extracts from Ziehl-Neelsen-stained slides for molecular detection of rifampin resistance and spoligotyping of Mycobacterium tuberculosis.

Authors:  A G M Van Der Zanden; E M Te Koppele-Vije; N Vijaya Bhanu; D Van Soolingen; L M Schouls
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.

Authors:  Christopher K Murphy; Steve Mullin; Marcia S Osburne; John van Duzer; Jim Siedlecki; Xiang Yu; Kathy Kerstein; Michael Cynamon; David M Rothstein
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.